We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DOJ Establishes Health Care Monopoly and Collusion Task Force

DOJ Establishes Health Care Monopoly and Collusion Task Force

May 14, 2024

The Department of Justice (DOJ) has formed a new enforcement arm — the Task Force Health Care Monopolies and Collusion (HCMC) — to guide the department’s policy approach for healthcare, but also to pursue investigations as well as civil and criminal enforcement in healthcare.

“The task force will identify and root out monopolies and collusive practices that increase costs, decrease quality and create single points of failure in the health care industry,” said Assistant Attorney General Jonathan Kanter of the DOJ’s Antitrust Division in a statement adding that “a small number of payers, providers and dominant intermediaries” have “consolidated their way to power in communities across the country,” gobbling up trillions of dollars.

The DOJ said the HCMC will consider “widespread competition concerns” regarding payer-provider consolidation as well as serial acquisitions, labor and quality of care, medical billing, healthcare IT services, access to and misuse of healthcare data and more.

To read the whole story, click here.

Related Topics

Drugs Devices Regulatory Affairs Regulatory Affairs

    Upcoming Events

    • 14May

      2024 Avoca Quality Consortium Summit

    • 23May

      Maximizing Trial Success Requires Evolving Feasibility and Recruitment Strategies

    • 30May

      FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule

    • 13Jun

      FDA in 2024 and Beyond: What Election-Year Changes Mean for Your Business

    • 20Jun

      Inspection Readiness for EU GMP Annex 1 – Manufacture of Sterile Medicinal Products

    • 21Oct

      MAGI@home Clinical Research Conference 2024

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • FDA, USDA and EPA to Coordinate on Biotechnology Products

    • Software Glitch Brings Class I Recall of Mobile App for Insulin Pump

    • DOJ Establishes Health Care Monopoly and Collusion Task Force

    • MDR Violations Merit Company an FDA Warning Letter

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing